EMPA-KIDNEY also provided solid evidence that the effect of the drug was maintained in patients with severe CKD at baseline (eGFR of 20–30 mL/min/1.73 m2), finally confirming that even patients with advanced CKD benefit from SGLT2 inhibition. This evidence concerns the gene SLC5A2 and chronic kidney disease.